Biotalys Reports 2025 Financial Results with €8.0 Million Cash Runway and Strategic Refocus

Ghent, Belgium (Substrate) -- Biotalys announced consolidated financial results for 2025 on April 29, 2026, prepared in accordance with IFRS as adopted by the European Union. The annual report, including the full financial report for 2025, is published on the company's website. 0 million, providing a financial runway until the end of May 2026.

The company is negotiating with investors regarding financing options as of April 29, 2026. Biotalys announced its intention to proceed with a strategic refocus in early February 2026, which the board confirmed on April 29, 2026. As part of this, Biotalys is proceeding with a streamlined operational model and has suspended its early-stage activities to reduce operating expenses while safeguarding the long-term value of its technology platform.

Biotalys will prioritize the development and regulatory advancement of its lead biofungicide assets and focus commercial preparation efforts on markets with the highest near-term potential. The strategic refocus aims to result in a significant reduction of cash burn until the end of 2028.

Management hosted a conference call and live webcast at 15:00 CEST, 14:00 GMT, or 09:00 AM ET on April 29, 2026, to discuss the results and outlook.

EPA for its first candidate biofungicide EVOCA, announced in December 2025. EVOCA controls the fungal diseases Botrytis (grey mold) and powdery mildew for fruit and vegetable growers. The Dutch regulator provided a positive recommendation for EVOCA in 2025, with the Dutch Board for the Authorisation of Plant Protection Products (CTGB) recommending approval of its active ingredient throughout the European Union.

The Dutch Institute for Health and Environment (RIVM) confirmed no critical areas of concern for EVOCA and proposed its low-risk classification in 2025. S.

State. Biotalys released results of initial field trials for BioFun-6 in Europe and the United States in March 2025. BioFun-6 achieved the same level of performance as EVOCA at lower dosage rates in those trials.

BioFun-6 targets Botrytis and powdery mildew in high-value fruits and vegetables and performed well in independent academic trials by University of California-Davis in 2025. Throughout 2025, Biotalys advanced BioIns-2, its first bioinsecticide, in collaboration with Syngenta Crop Protection, achieving a first research milestone in April 2026.

The company also progressed BioFun-7 in partnership with the Gates Foundation in 2025; BioFun-7 targets leafspot disease.

As part of the strategic refocus, Biotalys is opening BioFun-4 for R&D collaboration with third parties as of April 29, 2026; BioFun-4 targets Oomycetes in potatoes and fruits and vegetables. The strain engineering and process development for EVOCA and BioFun-6 is on track to meet commercial timelines as of April 29, 2026.

In May 2025, Biotalys announced a partnership with AgroFresh to protect produce post-harvest and reduce global food waste from fungal decay. The partnership focuses on developing and commercializing sustainable biological solutions to keep high-value and highly perishable crops fresher for longer with less chemical residues.

BIO, a leading Danish precision fermentation technology company, to accelerate production of its protein-based biocontrol solutions.

BIO's proprietary fermentation platform to support the production of Biotalys' AGROBODY agricultural biocontrol products at commercially competitive costs. In March 2025, Biotalys appointed Toni Bucci to its Board of Directors; Toni Bucci is a seasoned agriculture and biotech executive providing expert guidance to help the company navigate its path to commercialization and accelerate its impact in sustainable agriculture.

In May 2025, Biotalys appointed Luc Van fraeyenhoven as Chief Financial Officer to provide cost-conscious and operationally sound financial leadership on both long-term strategies and day-to-day finance operations.

EPA approval of our first biocontrol, EVOCA, further validating our AGROBODYTM platform. Alongside our regulatory progress, we also established a strategic partnership with AgroFresh, leveraging EVOCA’s favorable safety profile in the post-harvest market.

" Biotalys is listed on Euronext under BTLS. Separately, Amaroq Ltd. will release its financial results for the first quarter of 2026 on May 13, 2026, covering the period from January to March 2026. Amaroq Ltd.

Will host a capital markets update event for investors and analysts on May 13, 2026, beginning at 14:30 BST in London, with a live webcast available for remote participants; a recording will be made available following the event. Amaroq Ltd. is listed on AIM, NASDAQ Iceland under the ticker AMRQ, and OTCQX under AMRQF.

The company focuses on developing mining projects in Greenland.